Results 101 to 110 of about 9,833 (206)

Comparative Effectiveness and Safety of Acarbose and Vildagliptin in Type 2 Diabetes Management: A Real-World Observational Study in an Indian Population

Clinical Diabetology
OBJECTIVE: To evaluate and compare the real-world effectiveness and safety profiles of Acarbose and Vildagliptin in patients with type 2 diabetes (T2D), with an additional focus on their impacts on the gut microbiota.
Shambo Samrat Samajdar, Shatavisa Mukherjee, Rutul Gokalani, Supratik Bhattacharyya, Banshi Saboo, Shashank Joshi   +5 more
doaj   +1 more source

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study

Diabetes, Metabolic Syndrome and Obesity, 2016
Ahmed AK Hassoun,1 Md Faruque Pathan,2 Rita C Medlej,3,4 Monira Alarouj,5 Inass Shaltout,6 Manoj S Chawla,7 Ditte Knap,8 Julius A Vaz9 1Dubai Diabetes Centre, Dubai, UAE; 2Department of Endocrinology, BIRDEM Hospital, Dhaka, Bangladesh; 3Department of ...
Hassoun AAK, Pathan MF, Medlej RC, Alarouj M, Shaltout I, Chawla MS, Knap D, Vaz JA   +7 more
doaj  

Molecular cloning and biochemical characterization of Xaa-Pro dipeptidyl-peptidase from Streptococcus mutans and its inhibition by anti-human DPP IV drugs

, 2016
Streptococcus mutans harbours an intracellular, human DPP IV-analogous enzyme Xaa-Pro dipeptidyl-peptidase (EC 3.4.14.11). According to previous reports, an extracellular isozyme in S. gordonii and S. suis has been associated with virulence.
De, A, Lupidi, Giulio, Petrelli, Dezemona, Vitali, Luca Agostino   +3 more
core   +1 more source

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

Vascular Health and Risk Management, 2011
Anja Schweizer1, Sylvie Dejager2, James E Foley3, Wolfgang Kothny31Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharma SAS, Rueil-Malmaison, France; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAAim: Analyzing safety aspects of a drug ...
Schweizer A, Dejager S, Foley JE, Kothny W   +3 more
doaj  

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

Vascular Health and Risk Management, 2010
James E Foley1, Jens Jordan21Clinical Research and Development, Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA; 2Institute for Clinical Pharmacology, Hannover Medical School, Hannover, GermanyAbstract: Various factors may confound how
James E Foley, Jens Jordan
doaj  

Vildagliptin promotes diabetic foot ulcer healing through autophagy modulation

Diabetology & Metabolic Syndrome
The study aimed to investigate the molecular mechanisms underlying the effects of Vildagliptin on the healing of diabetic foot ulcers (DFUs). The research compared patients who received 12 weeks of Vildagliptin treatment to those who did not.
Erik Biros, Venkat Vangaveti, Usman Malabu   +2 more
doaj   +1 more source

A comparative study on vildagliptin brand and its generic equivalents using dissolution test as quality control measure tool

Scientific Reports
Market drugs including brand or generic with poor quality, don’t meet the acceptable standard guidelines. Vildagliptin is an important antidiabetic drugs used in monotherapy or in combinations protocols for treatment of diabetes mellites.
Ghadah H. Altoum, Fouza K. AL-Enazi, Mubarl M. Abudahash, Reem A. AL-Fadhli, Naif Alenzi   +4 more
doaj   +1 more source

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

Vascular Health and Risk Management, 2013
Anja Schweizer,1 James E Foley,2 Wolfgang Kothny,2 Bo Ahrén31Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3Department of Clinical Sciences, Lund University, Lund, SwedenAbstract: Due to ...
Schweizer A, Foley JE, Kothny W, Ahrén B   +3 more
doaj  

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly

Drug Design, Development and Therapy, 2014
Antoni Sicras-Mainar,1 Ruth Navarro-Artieda2 1Dirección de Planificación, Badalona Serveis Assistencials SA, 2Documentación Médica, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain Background: The aim of this study ...
Sicras-Mainar A, Navarro-Artieda R
doaj  

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease? [PDF]

, 2015

core   +1 more source